Comparing PI3K/Akt Inhibitors Used in Ovarian Cancer Treatment

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Epithelial ovarian carcinoma (EOC) is a highly lethal gynecological malignancy.
• The phosphoinositide 3-kinase (PI3K)/Akt pathway is implicated in ovarian cancer progression and chemoresistance.
• Elevated Akt phosphorylation at Ser473 correlates with poor patient outcomes.

Purpose of the Study:

• To evaluate the efficacy of three AZD compounds targeting PI3K/Akt inhibition in ovarian cancer.
• To investigate Akt regulation and downstream effects in ovarian cancer cell lines and a xenograft model.

Main Methods:

• Testing AZD compounds (AZD8835, AZD8186, AZD5363) in eight ovarian cancer cell lines.
• Utilizing a NOD-SCID xenograft mouse model to assess tumor formation and growth inhibition.
• Analyzing Akt phosphorylation, downstream effector inhibition (4E-BP1, p70S6 kinase), and gene expression (COL11A1, BRCA1/BRCA2, p-ERK).

Main Results:

• AZD8835 and AZD8186 inhibited Akt phosphorylation; AZD5363 augmented Ser473 phosphorylation but inhibited downstream effectors.
• AZD8835 and AZD5363 sensitized chemoresistant cells to cisplatin and paclitaxel.
• AZD5363 inhibited COL11A1 expression. AZD8835 and AZD5363 significantly reduced tumor formation in vivo.
• AZD8835 affected BRCA1/BRCA2 and p-ERK in a KRAS-mutated cell line.

Conclusions:

• PI3K/Akt pathway is crucial for ovarian cancer progression and chemoresistance.
• AZD8835 and AZD5363 demonstrate significant therapeutic potential as agents against EOC.
• Targeting PI3K/Akt with specific AZD compounds offers a promising strategy for ovarian cancer treatment.